Logo image of KOVO.CA

KOVO+ HOLDINGS INC (KOVO.CA) Stock Fundamental Analysis

TSX-V:KOVO - TSX Venture Exchange - CA5007421012 - Common Stock - Currency: CAD

0.02  0 (0%)

Fundamental Rating

1

KOVO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 8 industry peers in the Health Care Technology industry. Both the profitability and financial health of KOVO have multiple concerns. KOVO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KOVO had negative earnings in the past year.
In the past year KOVO has reported a negative cash flow from operations.
KOVO.CA Yearly Net Income VS EBIT VS OCF VS FCFKOVO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -1M -2M -3M -4M -5M

1.2 Ratios

KOVO has a Return On Assets of -51.60%. This is in the better half of the industry: KOVO outperforms 62.50% of its industry peers.
Industry RankSector Rank
ROA -51.6%
ROE N/A
ROIC N/A
ROA(3y)-35.27%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KOVO.CA Yearly ROA, ROE, ROICKOVO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KOVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KOVO.CA Yearly Profit, Operating, Gross MarginsKOVO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -10 -20 -30 -40 -50

More info and screens

0

2. Health

2.1 Basic Checks

KOVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
KOVO has more shares outstanding than it did 1 year ago.
The debt/assets ratio for KOVO is higher compared to a year ago.
KOVO.CA Yearly Shares OutstandingKOVO.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M 80M 100M
KOVO.CA Yearly Total Debt VS Total AssetsKOVO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

KOVO has an Altman-Z score of -3.16. This is a bad value and indicates that KOVO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of KOVO (-3.16) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.16
ROIC/WACCN/A
WACC5.48%
KOVO.CA Yearly LT Debt VS Equity VS FCFKOVO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M 4M -4M

2.3 Liquidity

KOVO has a Current Ratio of 0.06. This is a bad value and indicates that KOVO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.06, KOVO is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
KOVO has a Quick Ratio of 0.06. This is a bad value and indicates that KOVO is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.06, KOVO is doing worse than 75.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
KOVO.CA Yearly Current Assets VS Current LiabilitesKOVO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

KOVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.51%, which is quite good.
The Revenue has been growing slightly by 6.55% in the past year.
Measured over the past years, KOVO shows a very strong growth in Revenue. The Revenue has been growing by 21.39% on average per year.
EPS 1Y (TTM)15.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.42%
Revenue 1Y (TTM)6.55%
Revenue growth 3Y21.39%
Revenue growth 5YN/A
Sales Q2Q%4.26%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KOVO.CA Yearly Revenue VS EstimatesKOVO.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KOVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KOVO.CA Price Earnings VS Forward Price EarningsKOVO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KOVO.CA Per share dataKOVO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

KOVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KOVO+ HOLDINGS INC

TSX-V:KOVO (6/20/2025, 7:00:00 PM)

0.02

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-29 2024-08-29
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners79.06%
Ins Owner ChangeN/A
Market Cap3.54M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.08
BVpS-0.03
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.27%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.2%
Cap/Sales 1.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z -3.16
F-Score2
WACC5.48%
ROIC/WACCN/A
Cap/Depr(3y)41.45%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.97%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.42%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.55%
Revenue growth 3Y21.39%
Revenue growth 5YN/A
Sales Q2Q%4.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-259.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-455.65%
OCF growth 3YN/A
OCF growth 5YN/A